Incyte and Syndax Present Additional Data from Positive AGAV

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment


- Data are...

Related Keywords

Delaware , United States , San Diego , California , American , Michaela Metzger , Daniel Wolff , Pabloj Cagnoni , Kaplan Meier , Company On Twitter , Linkedin , Development Incyte , Exchange Commission , American Society Of Hematology Annual Meeting , Professor At University Hospital Regensburg , Drug Administration , Syndax Pharmaceuticals , Syndax Pharmaceuticals Nasdaq , Head Of Research , Plenary Scientific Session , American Society , Hematology Annual Meeting , Lee Symptom Scale , Chief Executive Officer , Senior Physician , University Hospital , Biologics License Application , Orphan Drug Designation , Modified Lee Symptom , Private Securities Litigation Reform Act , Immunology Insights , Real World Treatment , Markets ,